- Home
- DAVA vs PHVS Comparison
DAVA vs PHVS Comparison
Compare DAVA & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAVA
- PHVS
- Stock Information
- Founded
- DAVA 2000
- PHVS 2015
- Country
- DAVA United Kingdom
- PHVS Switzerland
- Employees
- DAVA N/A
- PHVS N/A
- Industry
- DAVA EDP Services
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- DAVA Technology
- PHVS Health Care
- Exchange
- DAVA Nasdaq
- PHVS Nasdaq
- Market Cap
- DAVA 874.0M
- PHVS 909.5M
- IPO Year
- DAVA 2018
- PHVS 2021
- Fundamental
- Price
- DAVA $16.43
- PHVS $16.69
- Analyst Decision
- DAVA Buy
- PHVS Buy
- Analyst Count
- DAVA 8
- PHVS 6
- Target Price
- DAVA $29.13
- PHVS $37.17
- AVG Volume (30 Days)
- DAVA 1.5M
- PHVS 65.1K
- Earning Date
- DAVA 05-14-2025
- PHVS 05-13-2025
- Dividend Yield
- DAVA N/A
- PHVS N/A
- EPS Growth
- DAVA N/A
- PHVS N/A
- EPS
- DAVA 0.40
- PHVS N/A
- Revenue
- DAVA $1,007,631,882.00
- PHVS N/A
- Revenue This Year
- DAVA $6.33
- PHVS N/A
- Revenue Next Year
- DAVA $0.07
- PHVS N/A
- P/E Ratio
- DAVA $40.93
- PHVS N/A
- Revenue Growth
- DAVA 5.95
- PHVS N/A
- 52 Week Low
- DAVA $14.00
- PHVS $11.51
- 52 Week High
- DAVA $34.94
- PHVS $25.50
- Technical
- Relative Strength Index (RSI)
- DAVA 46.41
- PHVS 52.08
- Support Level
- DAVA $14.64
- PHVS $15.91
- Resistance Level
- DAVA $16.54
- PHVS $18.00
- Average True Range (ATR)
- DAVA 0.67
- PHVS 0.80
- MACD
- DAVA 0.20
- PHVS -0.03
- Stochastic Oscillator
- DAVA 77.17
- PHVS 46.26
About DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.